Emmanuel  Seront,Ledoux  B,Samartzi V,van Marcke de  Lummen C,
An atypical presentation of ifosfamide-induced encephalopathy and its successful treatment with methylene blue
Clinical Oncology and Research
2018
2613-4942
http://dx.doi.org/10.31487/j.COR.2018.10.009
https://www.sciencerepository.org/an-atypical-presentation-of-ifosfamide-induced-encephalopathy-and-its-successful-treatment-with-methylene-blue_COR-1-109 
Abstract: Confusion remains a frequent event appearing during cancer course; many causes have to be excluded,
including antitumoral agent-induced encephalopathy. Ifosfamide-induced encephalopathy is often
underdiagnosed due to aspecific symptoms. The manifestations of this encephalopathy are usually moderate
and spontaneously reversible but may also lead to coma and death. We describe symptoms of dysarthria and
ataxia appearing following the second course of ifosfamide in a patient treated for sarcoma. Furthermore,
methylene blue administration instantaneously reversed the process. This case report highlights an atypical
presentation of encephalopathy induced by ifosfamide and the importance to consider methylene blue in
this setting.
Keywords: Breast cancer, drug delivery, cytotoxicity effects, hydroxyurea nano-transfersomes